HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that it will present at the 2018 Atlantic Venture Forum Technology Showcase. The event takes place June 28-29, 2018 in Halifax, Canada.
Appili’s Chief Executive Officer Kevin Sullivan will present a corporate overview and update on the Company’s active pipeline and business development programs.
Presentation details are as follows:
Date: Thursday, June
28, 2018
Time: 2 p.m. Atlantic time
Session:
Growth Stage Presenting Companies
Location: Halifax Marriott
Harbourfront Hotel
Learn more about the Technology Showcase.
About Appili Therapeutics
Appili Therapeutics, Inc., was
founded to advance the global fight against infectious disease by
matching clearly-defined patient needs with drug development programs
that provide solutions to existing challenges patients, doctors and
society face in this challenging disease space. Balancing near-to-market
product candidates with higher-risk but potentially transformative
early-stage programs, Appili’s growing pipeline includes assets being
developed by Appili as well as an active licensing program. ATI-1501
employs Appili’s proprietary, taste-masked, oral-suspension technology
with metronidazole for the growing number of pediatric and elderly
patients with difficulty swallowing. ATI-1503 is a drug discovery
program aimed at generating negamycin analogue candidates, a novel class
of antibiotics with broad-spectrum activity against Gram-negative
bacteria. Via an in-licensing program, Appili acquired the rights to
ATI-1701, a vaccine for tularemia, removing risk from a weaponized
bioterrorism pathogen. Headquartered in Halifax, Nova Scotia, with
offices in Mississauga, Ontario, Appili is pursuing worldwide
opportunities in collaboration with science and industry commercial
partners, governments and government agencies. For more information,
visit www.AppiliTherapeutics.com.